Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tony Bekaii-Saab, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00320749
First received: April 28, 2006
Last updated: November 8, 2013
Last verified: November 2013